The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

$ 8.50

4.8 (264) In stock

HER2-positive MedChemExpress (MCE) Life Science Reagents

Salinomycin suppresses STAT3 activation. (A) Basal levels of STAT3 and

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International

Cancers, Free Full-Text

Soeun Park's research works Korea University, Seoul (KU) and other places

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International

Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities - ScienceDirect

A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International

Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer

Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances - ScienceDirect

Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances - ScienceDirect

Salinomycin decreases the CD44+/CD24- stem-like population during

PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response